Drugs / FH-WT1-E50 TCR T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07645469 | Aug 2026 → Jul 2030 expected | acute myeloid leukemia | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FH-WT1-E50 TCR T | “If additional cells are available patients may receive a second infusion of azacitidine IV followed by FH-WT1-E50 TCR T cells IV, starting at 28 days, up to 1 year.” NCT07645469 ↗ |
| Action | Deplete | “T cells are infection fighting blood cells that can kill tumor cells.” NCT07645469 ↗ |
| Modality | Cell therapy | “The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize WT1” NCT07645469 ↗ |
| Route | Intravenous | “Given IV” NCT07645469 ↗ |
| Target | WT1 | “recognize WT1, a protein on the surface of cancer cells” NCT07645469 ↗ |